Myelodysplastic syndrome after autologous transplant for lymphoma.
Anderson
J R
JR
Vose
J
J
Kessinger
A
A
D000971:Antineoplastic Combined Chemotherapy Protocols; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006689:Hodgkin Disease / Q000628:therapy; D006801:Humans; D015993:Life Tables; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008466:Mechlorethamine / Q000009:adverse effects; D009190:Myelodysplastic Syndromes / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology*; D009381:Neoplasms, Radiation-Induced / Q000453:epidemiology / Q000209:etiology*; D011241:Prednisone / Q000009:adverse effects; D011344:Procarbazine / Q000009:adverse effects; D012307:Risk Factors; D014182:Transplantation, Autologous / Q000009:adverse effects; D014750:Vincristine / Q000009:adverse effects; D014916:Whole-Body Irradiation
D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone